Loading
The first drug approved for thyroid cancers that stopped responding to radioactive iodine.
DECISION, trial NCT00984282 sponsored by Bayer and reported in 2013, produced the first drug approved for differentiated thyroid cancers that stopped responding to radioactive iodine. It randomised 417 patients to sorafenib or placebo and met its primary progression-free survival endpoint, leading to FDA approval in November 2013, with hand-foot skin reaction and fatigue common. OnCo links it to thyroid cancer, kinase inhibitors, VEGF and BRAF as targets, the radioiodine-refractory term and Marcia S. Brose, and SELECT confirmed the class effect with a larger benefit for lenvatinib. Sorafenib has been largely displaced by lenvatinib but is still used, and whether it retains a niche in patients who cannot tolerate lenvatinib is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Radioiodine-refractory (RAI-R) thyroid cancer, VEGF / VEGFR, Thyroid cancer, Small-molecule kinase inhibitors.
Shares Bayer, VEGF / VEGFR, BRAF, Small-molecule kinase inhibitors.
Shares Radioiodine-refractory (RAI-R) thyroid cancer, Thyroid cancer, Small-molecule kinase inhibitors.
Shares DECISION: sorafenib in radioactive iodine-refractory differentiated thyroid cancer, Radioiodine-refractory (RAI-R) thyroid cancer, Thyroid cancer.
Shares BRAF, Thyroid cancer, Small-molecule kinase inhibitors.
Shares Bayer, VEGF / VEGFR, Small-molecule kinase inhibitors.
Shares VEGF / VEGFR, BRAF, Thyroid cancer, Small-molecule kinase inhibitors.
Shares Bayer, Small-molecule kinase inhibitors.